Acumen Pharmaceuticals, Inc. (ABOS) vs AirSculpt Technologies, Inc. (AIRS)
A side-by-side comparison of Acumen Pharmaceuticals, Inc. and AirSculpt Technologies, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ABOS
Acumen Pharmaceuticals, Inc.
$2.03HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
AIRS
AirSculpt Technologies, Inc.
$1.86HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ABOS vs AIRS
growth of $100 · dividends reinvested · last 5yABOS -84.8% (-31.4%/yr)AIRS -87.4% (-34.0%/yr)ABOS compounded faster over this window
ABOS AIRS
ABOS vs AIRS: by the numbers
- •ABOS is the larger company ($147M vs $131M market cap).
- •Both run net losses; ABOS's is the smaller (0.00% vs -7.79% net margin).
Metrics side by side
Valuation
| Metric | ABOS | AIRS |
|---|---|---|
| P/S ratio | N/A | 0.87 |
| P/B ratio | 2.56 | 1.25 |
| EV / EBITDA | N/A | 430.26 |
| FCF yield | N/A | 0.58% |
Profitability
| Metric | ABOS | AIRS |
|---|---|---|
| Gross margin | 0.00% | 57.63% |
| Operating margin | 0.00% | -7.85% |
| Net margin | 0.00% | -7.79% |
| ROE | -183.44% | -11.20% |
| ROIC | -118.67% | -7.01% |
Growth (annualized)
| Metric | ABOS | AIRS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 8.17% |
| FCF CAGR (5Y) | N/A | -52.36% |
| Total return CAGR (5Y) | -32.60% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.